Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Retained Earnings (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Retained Earnings for 16 consecutive years, with -$46.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 7.46% year-over-year to -$46.0 million, compared with a TTM value of -$46.0 million through Sep 2025, down 7.46%, and an annual FY2024 reading of $11.3 million, down 1.16% over the prior year.
  • Retained Earnings was -$46.0 million for Q3 2025 at China Pharma Holdings, down from -$45.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $12.5 million in Q2 2021 and bottomed at -$46.0 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$12.1 million, with a median of $11.3 million recorded in 2023.
  • The sharpest move saw Retained Earnings soared 146.09% in 2021, then tumbled 477.89% in 2024.
  • Year by year, Retained Earnings stood at -$32.2 million in 2021, then dropped by 12.32% to -$36.2 million in 2022, then surged by 131.63% to $11.5 million in 2023, then fell by 1.16% to $11.3 million in 2024, then crashed by 506.3% to -$46.0 million in 2025.
  • Business Quant data shows Retained Earnings for CPHI at -$46.0 million in Q3 2025, -$45.3 million in Q2 2025, and $11.3 million in Q1 2025.